DUBLIN–(BUSINESS WIRE)–The “Measles (Infectious Disease) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering.
Measles – Drugs In Development, 2021, provides an overview of the Measles (Infectious Disease) pipeline landscape.
Measles is a highly infectious viral disease. The virus lives in the mucus of the nose and throat of people with this infection. Physical contact, coughing and sneezing can spread the infection. Symptoms of measles are high temperature, sore eyes (conjunctivitis), and a runny nose usually occur first, small white spots usually develop inside the mouth a day or so later, diarrhea and vomiting.
Report Highlights
The report provides comprehensive information on the therapeutics under development for Measles (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Measles (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Measles and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 1, 1, 1, 4, 3 and 1 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 2, 1 and 1 molecules, respectively.
Measles (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Measles (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Measles (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
Introduction
Measles – Overview
- Measles – Therapeutics Development
Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
Measles – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Measles – Companies Involved in Therapeutics Development
- Beijing Minhai Biotechnology Co Ltd
- Biological E Ltd
- Cadila Healthcare Ltd
- Daiichi Sankyo Co Ltd
- Enesi Pharma Ltd
- GlaxoSmithKline Plc
- Indian Immunologicals Ltd
- Micron Biomedical Inc
- Panacea Biotec Ltd
- Sinovac Biotech Ltd
- Univercells SA
- Vaxxas Inc
- VBI Vaccines Inc
Measles – Drug Profiles
- (measles + mumps + rubella + varicella) vaccine – Drug Profile
- (measles + mumps + rubella) vaccine – Drug Profile
- (measles + rubella) vaccine – Drug Profile
- (measles [strain Edmonstons-Zagreb] + rubella [strain RA-27]) vaccine – Drug Profile
- (measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine – Drug Profile
- BK-1601 – Drug Profile
- ERDRP-0519 – Drug Profile
- measles vaccine – Drug Profile
- measles vaccine – Drug Profile
- Small Molecule for Measles – Drug Profile
- VN-0102 – Drug Profile
Measles – Dormant Projects
Measles – Product Development Milestones
Featured News & Press Releases
- May 05, 2021: Enesi Pharma achieves key milestone in development of thermostable solid-dose live vaccines against measles and rubella
- Mar 18, 2020: Vaxxas awarded US$5 million grant for clinical study of measles and rubella vaccination
- Nov 30, 2019: Vaxxas was awarded research and development fund of USD 4,997,693 from Bill & Melinda Gates Foundation
- Nov 30, 2016: Vaxxas was awarded research and development fund of USD 4,479,552 from Bill & Melinda Gates Foundation
Appendix
For more information about this report visit https://www.researchandmarkets.com/r/5an2w5
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900